Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 22;10(21):e39698.
doi: 10.1016/j.heliyon.2024.e39698. eCollection 2024 Nov 15.

A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia

Wee-Joo Chng  1   2 , Chandramouli Nagarajan  3   4 , Shang-Yi Huang  5 , Pankaj Malhotra  6 , Yu-Yan Hwang  7 , Vivian Blunk  8 , Manmohan Singh  9 , Lin Wang  9
Affiliations

A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia

Wee-Joo Chng et al. Heliyon. .

Abstract

Multiple myeloma (MM) accounts for almost 15 % of all neoplastic malignancies around the globe. This systematic review intends to analyse data on the treatment and management of MM in selected regions in Asia to identify and prioritize areas that need attention. A comprehensive review of original articles, published in English from 2005 to 2022, derived from the PubMed/MEDLINE database was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. There were 98 studies from select regions of Asia (China, India, Taiwan, Hong Kong, and Singapore) on newly diagnosed MM and relapsed/refractory MM. This review evaluated the trends in disease outcomes with the gradual shift in treatment regimens from doublet to triplet. Additionally, this review also explored autologous stem cell transplant outcome and anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy in MM patients. This is the first systematic review attempting to collect data on the utility and comparison of innovative agents and modifications in treatment regimens in the context of the Asian population. This review established that the body of evidence for the management of MM was generally of poor quality and there is a need for more versatile studies in the region. Novel and innovative drug regimens may help in combating the illness but consorted efforts by researchers, industry partners, policymakers, and the government are key factors in the long-term survival of MM patients. In the current systematic review, the authors have tried to give a comprehensive account of the available treatments, trends in MM management and prognosis for MM in Asia.

Keywords: Autologous stem cell transplant; B-cell maturation antigen targeted chimeric antigen receptor T-cell therapy; Newly diagnosed multiple myeloma; Proteasome inhibitors; Relapsed/refractory multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Chandramouli Nagarajan reports financial support was provided by Janssen. Chandramouli Nagarajan reports a relationship with Janssen that includes: board membership and speaking and lecture fees. Chandramouli Nagarajan reports a relationship with Amgen that includes: speaking and lecture fees. Chandramouli Nagarajan reports a relationship with AZ that includes: board membership and speaking and lecture fees. Chandramouli Nagarajan reports a relationship with Sanofi that includes: board membership. Chandramouli Nagarajan reports a relationship with Pfizer that includes: board membership. Chandramouli Nagarajan reports a relationship with BMS that includes: board membership. Vivian Blunk reports a relationship with Pfizer that includes: employment and equity or stocks. Manmohan Singh reports a relationship with Pfizer that includes: employment and equity or stocks. Lin Wang reports a relationship with Pfizer that includes: employment. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram of study selection for the systematic review.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kumar L., Ramavath D., Kataria B., Tiwari A., Raj A., Chellapuram S.K., Mookerjee A., Sahoo R.K., Malik P.S., Sharma A., Gupta R., Sharma O.D., Biswas A., Kumar R., Thulkar S., for AIIMS Myeloma Group High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: predictors of long-term outcome, Indian. J. Media Res. 2019;149:730–739. 110.4103/ijmr.ijmr_1593_18. - PMC - PubMed
    1. Zhou L., Yu Q., Wei G., Wang L., Huang Y., Hu K., Hu Y., Huang H. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer. 2021;21:606. doi: 10.1186/s12885-021-08280-y. - DOI - PMC - PubMed
    1. Padala S.A., Barsouk A., Barsouk A., Rawla P., Vakiti A., Kolhe R., Kota V., Ajebo G.H. Epidemiology, staging, and management of multiple myeloma. Med. Sci. Basel. Switz. 2021;9:3. doi: 10.3390/medsci9010003. - DOI - PMC - PubMed
    1. Rajkumar S.V. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am. J. Hematol. 2022;97:1086–1107. doi: 10.1002/ajh.26590. - DOI - PMC - PubMed
    1. Rajkumar S.V. Multiple myeloma: every year a new standard? Hematol. Oncol. 2019;37:62–65. doi: 10.1002/hon.2586. - DOI - PMC - PubMed

LinkOut - more resources